These three “double-positive” patients became all FISH positive at tumor re-biopsy; the two EGFR/ROS1 patients had been treated with EGFR-TKIs, and the confirmed FISH positivity at tumor re-biopsy seems to suggest an expansion of the ROS1-positive clone under EGFR target therapy pressure. This evidence concerns the gene EGFR and neoplasm.